Building Immune Organoids From Children's Cancer Tissue
Lab-grown immune models made from tumor and skin samples of children with cancer.
Plain-language title generated from the registry record
Registry title: Engineering Immune Organoids to Study Pediatric Cancer
Key facts
- Where
- Paris and Villejuif, FranceSee the 2 sites
Where in France
- Hôpital NeckerParis, FranceTaking people
- Gustave RoussyVillejuif, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Gustave Roussy, Cancer Campus, Grand Paris
- Trial code
- NCT05890781
- Record updated
- 9 February 2026
- Original description
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)Read full original descriptionShow less
Engineering Immune Organoids to Study Pediatric Cancer (IMMUNE-ORGANOIDS)
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
Inclusion: Age at diagnosis ≤ 25 years except for patients with malignant gliomas and renal tumors for whom no upper age limit is applied; Medical suspicion or diagnosis of one of the following diseases, regardless of stage:; Brain tumors; Renal tumors; Neuroblastoma; Sarcomas; Adult patient or parents or guardians should understand, sign and date the appropriate written informed consent from prior to any protocol-specific procedures performed. Patient should be able and willing to comply with study visits and procedures as per protocol; Affiliated to a social security system or beneficiary of the same.
Exclusion: Any histology not mentioned in the inclusion criteria; Adult patient or parents/guardians incapable/incapable of giving its/their consent; Patients deprived of their liberty by a judicial or administrative decision.